IQVIA Holdings Inc. (NYSE:IQV) Short Interest Down 5.8% in October

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 2,910,000 shares, a decrease of 5.8% from the September 30th total of 3,090,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 2.9 days. Approximately 1.6% of the shares of the company are short sold.

IQVIA Price Performance

Shares of IQVIA stock traded down $7.01 during trading on Thursday, hitting $209.03. 2,089,391 shares of the stock traded hands, compared to its average volume of 1,078,471. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a market cap of $38.11 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 2.09 and a beta of 1.49. The firm’s fifty day moving average is $235.88 and its 200-day moving average is $230.06. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays dropped their price objective on IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a report on Tuesday, October 15th. Robert W. Baird increased their price objective on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Morgan Stanley increased their price objective on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Argus raised IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $267.27.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently bought and sold shares of the stock. First Foundation Advisors grew its position in IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after acquiring an additional 43 shares during the last quarter. Team Hewins LLC grew its position in IQVIA by 5.0% during the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after acquiring an additional 46 shares during the last quarter. Invera Wealth Advisors LLC grew its position in IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after acquiring an additional 46 shares during the last quarter. Covestor Ltd grew its position in IQVIA by 45.3% during the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.